Piotr Lewczuk1, Johannes Kornhuber1, Jon B Toledo2, John Q Trojanowski2, Malgorzata Knapik-Czajka2, Oliver Peters3, Jens Wiltfang4, Leslie M Shaw2. 1. Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. 2. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Psychiatry and Psychotherapy, Charité Berlin, Berlin, Germany. 4. Department of Psychiatry and Psychotherapy, Georg-August Universität Göttingen, Göttingen, Germany.
Abstract
BACKGROUND: In previous studies, a dichotomous stratification of subjects into "cerebrospinal fluid (CSF) normal" and "CSF pathologic" was used to investigate the role of biomarkers in the prediction of progression to dementia in pre-dementia/mild cognitive impairment subjects. With the previously published Erlangen Score Algorithm, we suggested a division of CSF patterns into five groups, covering all possible CSF result combinations based on the presence of pathologic tau and/or amyloid-β CSF values. OBJECTIVE: This study aimed to validate the Erlangen Score diagnostic algorithm based on the results of biomarkers analyses obtained in different patients cohorts, with different pre-analytical protocols, and with different laboratory analytical platforms. METHODS: We evaluated the algorithm in two cohorts of pre-dementia subjects: the US-Alzheimer's Disease Neuroimaging Initiative and the German Dementia Competence Network. RESULTS: In both cohorts, the Erlangen scores were strongly associated with progression to Alzheimer's disease. Neither the scores of the progressors nor the scores of the non-progressors differed significantly between the two projects, in spite of significant differences in the cohorts, laboratory methods, and the samples treatment. CONCLUSIONS: Our findings confirm the utility of the Erlangen Score algorithm as a useful tool in the early neurochemical diagnosis of Alzheimer's disease.
BACKGROUND: In previous studies, a dichotomous stratification of subjects into "cerebrospinal fluid (CSF) normal" and "CSF pathologic" was used to investigate the role of biomarkers in the prediction of progression to dementia in pre-dementia/mild cognitive impairment subjects. With the previously published Erlangen Score Algorithm, we suggested a division of CSF patterns into five groups, covering all possible CSF result combinations based on the presence of pathologic tau and/or amyloid-β CSF values. OBJECTIVE: This study aimed to validate the Erlangen Score diagnostic algorithm based on the results of biomarkers analyses obtained in different patients cohorts, with different pre-analytical protocols, and with different laboratory analytical platforms. METHODS: We evaluated the algorithm in two cohorts of pre-dementia subjects: the US-Alzheimer's Disease Neuroimaging Initiative and the German Dementia Competence Network. RESULTS: In both cohorts, the Erlangen scores were strongly associated with progression to Alzheimer's disease. Neither the scores of the progressors nor the scores of the non-progressors differed significantly between the two projects, in spite of significant differences in the cohorts, laboratory methods, and the samples treatment. CONCLUSIONS: Our findings confirm the utility of the Erlangen Score algorithm as a useful tool in the early neurochemical diagnosis of Alzheimer's disease.
Authors: Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2011-02-11 Impact factor: 17.088
Authors: Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Kris A Johnson; David S Knopman; Bradley F Boeve; Gregory A Jicha; Robert J Ivnik; Glenn E Smith; Eric G Tangalos; Heiko Braak; Emre Kokmen Journal: Arch Neurol Date: 2006-05
Authors: Barbara Mroczko; Magdalena Groblewska; Marzena Zboch; Agnieszka Kulczyńska; Olga M Koper; Maciej Szmitkowski; Johannes Kornhuber; Piotr Lewczuk Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: F Hulstaert; K Blennow; A Ivanoiu; H C Schoonderwaldt; M Riemenschneider; P P De Deyn; C Bancher; P Cras; J Wiltfang; P D Mehta; K Iqbal; H Pottel; E Vanmechelen; H Vanderstichele Journal: Neurology Date: 1999-05-12 Impact factor: 9.910
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Piotr Lewczuk; Hermann Esselmann; Mirko Bibl; Georg Beck; Juan Manuel Maler; Markus Otto; Johannes Kornhuber; Jens Wiltfang Journal: J Mol Neurosci Date: 2004 Impact factor: 2.866
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Philipp Spitzer; Roland Lang; Timo J Oberstein; Piotr Lewczuk; Natalia Ermann; Hagen B Huttner; Ilias Masouris; Johannes Kornhuber; Uwe Ködel; Juan M Maler Journal: Front Aging Neurosci Date: 2018-05-24 Impact factor: 5.750
Authors: Oskar Hansson; John Seibyl; Erik Stomrud; Henrik Zetterberg; John Q Trojanowski; Tobias Bittner; Valeria Lifke; Veronika Corradini; Udo Eichenlaub; Richard Batrla; Katharina Buck; Katharina Zink; Christina Rabe; Kaj Blennow; Leslie M Shaw Journal: Alzheimers Dement Date: 2018-03-01 Impact factor: 21.566
Authors: Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk Journal: Alzheimers Res Ther Date: 2019-04-22 Impact factor: 6.982
Authors: Janine Utz; Judith Berner; Luis Enrique Muñoz; Timo Jan Oberstein; Johannes Kornhuber; Martin Herrmann; Juan Manuel Maler; Philipp Spitzer Journal: Front Aging Neurosci Date: 2021-07-06 Impact factor: 5.750